Targeted therapies used sequentially in metastatic renal cell cancer: Overall results from a large experience

Expert Review of Anticancer Therapy

Volumn 11, Issue 11, 2011, Pages 1631-1640

  Procopio, Giuseppe ^a   Verzoni, Elena ^a   Iacovelli, Roberto ^a   Guadalupi, Valentina ^a   Gelsomino, Francesco ^a   Buzzoni, Roberto ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

mTOR inhibitors; Renal cell carcinoma; Sorafenib; Sunitinib; Targeted therapies

Indexed keywords

AXITINIB; BEVACIZUMAB; EVEROLIMUS; SORAFENIB; SUNITINIB; TEMSIROLIMUS; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; HAND FOOT SYNDROME; HEART FAILURE; HEMATURIA; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; NAUSEA; OVERALL SURVIVAL; RASH; RENAL CELL CARCINOMA; RETROSPECTIVE STUDY; SURVIVAL RATE; KIDNEY CARCINOMA; KIDNEY TUMOR; METHODOLOGY; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84858710583     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.154     Document Type: Article

References (38)

1. Lindblad P. Epidemiology of renal cell carcinoma. Scand. J. Surg. 93(2), 88-96 (2004).
2. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA 281(17), 1628-1631 (1999).
3. Bos SD, Mellema CT, Mensink HJ. Increase in incidental renal cell carcinoma in the northern part of The Netherlands. Eur. Urol. 37(3), 267-270 (2000).
4. Mevorach RA, Segal AJ, Tersegno ME, Frank IN. Renal cell carcinoma: incidental diagnosis and natural history: review of 235 cases. Urology 39(6), 519-522 (1992).
5. Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J. Urol. 167(1), 57-60 (2002).
6. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J. Urol. 166(5), 1611-1623 (2001).
7. Atzpodien J, Royston P, Wandert T, Reitz M. Metastatic renal carcinoma comprehensive prognostic system. Br. J. Cancer 88(3), 348-353 (2003).
8. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am. J. Surg. Pathol. 27(5), 612-624 (2003).
9. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer. J. Clin. 54(1), 8-29 (2004).
10. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J. Urol. 163(2), 408-417 (2003).
11. Oudard S, George D, Medioni J et al. Treatment options in renal cell carcinoma: past, present and future. Ann. Oncol. 18(Suppl. 10), 25-31 (2007).
12. Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin. Cancer. Res. 10(Suppl.), 6342-6346 (2004).
13. Hutson TE. Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Clinical Evidence. The Oncologist 16(Suppl. 2), 14-22 (2011).
14. Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 115(1), 61-67 (2009).
15. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet 372(9637), 449-456 (2008).
16. Hutson TE, Bukowski RM, Cowey CL, Figlin R, Escudier B, Sternberg CN. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit. Rev. Oncol. Hematol. 77(1), 48-62 (2011).
17. Beck J, Procopio G, Bajetta E et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large openlabel study in diverse community settings. Ann. Oncol. 22(8), 1812-1823 (2011).
18. Grünwald V, Heinzer H, Fiedler W. Managing side effects of angiogenesis inhibitors in RCC. Onkologie 30, 519-524 (2007).
19. Ivanyi P, Winkler T, Ganser A, Reuter C, Grünwald V. Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib. Dtsch. Arztebl. Int. 105(13), 232-237 (2008).
20. Procopio G, Verzoni E, Guadalupi V et al. Sequential use of sorafenib (So) followed by sunitinib (Su) in metastatic renal cell cancer (mRCC): a single-institution experience [abstract]. Presented at: Genitourinary Cancers Symposium. Orlando, FL, USA, 26-28 February 2009 (Abstract 319).
21. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17(8), 2530-2540 (1999).
22. Silverman SL. From randomized controlled trials to observational studies. Am. J. Med. 122(2), 114-120 (2009).
23. Porta C, Paglino C, Cartenì G et al. Sequencing tyrosine kinase inhibitors or immediately switching to mTOR inhibitors in advanced kidney cancer: a critical review. EJCMO (2011) (In Press).
24. Eichelberg C, Heuer R, Chun FK et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur. Urol. 54(6), 1373-1378 (2008).
25. Sablin MP, Negrier S, Ravaud A et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J. Urol. 182, 29-34 (2009).
26. Zimmerman K, Schmittel A, Steiner U et al. Sunitinib treatment for patients with advanced clear cell renal-cell carcinoma after progression on sorafenib. Oncology 76(5), 350-354 (2009).
27. Garcia JA, Hutson TE, Elson P et al. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer 116(23), 5383-5390 (2010).
28. NCCN Clinical Practice Guidelines in Oncology™Kidney Cancer. Version 2.2010. © 2009 National Comprehensive Cancer Network, Inc www.nccn.org/professionals/physician_gls/f_guidelines.asp#site (Accessed 20 March 2011)
29. ClinicalTrials.gov. NCT00631371. Study Comparing Bevacizumab + Temsirolimus vs Bevacizumab + Interferon-Alfa in Advanced Renal Cell Carcinoma Subjects (INTORACT) www.clinicaltrials.gov/ct2/show/NCT006 31371?term=NCT00631371&rank=1 (Accessed 22 March 2011)
30. ClinicalTrials.gov. NCT00378703. Bevacizumab, Sorafenib, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer www.clinicaltrials.gov/ct2/show/NCT003 78703?term=NCT00378703&rank=1 (Accessed 22 March 2011)
31. ClinicalTrials.gov. NCT00619268. Combination of Temsirolimus and Bevacizumab in Patients with Metastatic Renal Cell Carcinoma (TORAVA) www.clinicaltrials.gov/ct2/show/NCT006 19268?term=NCT00619268&rank=1 (Accessed 22 March 2011)
32. ClinicalTrials.gov. NCT00719264. Safety and Efficacy of Bevacizumab Plus RAD 001 Versus Interferon Alfa-2a and Bevacizumab in Adult Patients With Kidney Cancer www.clinicaltrials.gov/ct2/show/NCT007 19264?term=NCT00719264&rank=1 (Accessed 22 March 2011)
33. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer. V. 2.2010 www.nccn.org/professionals/physician_gls/PDF/kidney.pdf (Accessed 22 March 2011)
34. Ljungberg B, Cowan N, Hanbury DC et al. European Association of Urology Guidelines on Renal Cell Carcinoma (2010) www.uroweb.org/gls/pdf/Renal%20Cell%20Carcinoma%202010.pdf (Accessed 22 March 2011)
35. ClinicalTrials.gov. NCT00732914. A Phase III Randomized Sequential Open-Label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Sunitinib Versus Sunitinib Followed by Sorafenib in the Treatment of First-Line Advanced/Metastatic Renal Cell Carcinoma http://clinicaltrials.gov/ct2/show/NCT00732914 (Accessed 22 March 2011)
36. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (Accessed 22 March 2011)
37. ClinicalTrials.gov http://clinicaltrials.gov/ct2/show/NCT00930033 (Accessed 25 August 2011)
38. EORTC protocol 30073-SURTIME www.eortc.be/protoc/details.asp?protocol=30073 (Accessed 25 August 2011)